Skip to main content

Advertisement

SpringerLink
Log in

Hand Eczema: Treatment Options

  • Contact Dermatitis (M Gonçalo, Section Editor)
  • Published:
Current Treatment Options in Allergy Aims and scope Submit manuscript

A Correction to this article was published on 19 December 2017

This article has been updated

Abstract

Purpose of review

Hand eczema is a common disease, it affects young people, is often work-related, and the burden of the disease is significant for the individual as well as for society. Factors to be considered when choosing a treatment strategy are, among others, whether the eczema is acute or chronic, the severity of the disease, and the specific sub-diagnosis of hand eczema, which relates to the etiology as well as the morphology of the disease. Optimal treatment is still a challenge. This review seeks to provide an overview of the most updated treatment of hand eczema.

Recent findings

Treatment options comprise patient education with information on hand eczema prevention and basic treatment and for patients with allergic contact dermatitis also with information about allergen avoidance. Topical treatment is primarily topical topical corticosteroids, which is—and has been for many years—first-line treatment for hand eczema, to be used for a limited period of time. Topical calcineurin inhibitors are widely used as off-label treatment for hand eczema; however, evidence for efficacy is sparse. Physical treatment with UVB and PUVA is effective, although time-consuming and sometimes too troublesome for the patients. With respect to systemic therapy, this is reserved for a patient with severe and long-lasting hand eczema. Alitretinoin is the only systemic therapy, which is licensed for severe chronic hand eczema, while other systemic therapies are also effective, but off-label use. Systemic treatment will in most cases be prescribed from 4 months and up to several years, and should always be accompanied by regular blood sample check.

Summary

topical corticosteroids are the mainstay primary choice of medical treatment, but should not be continued on a daily basis for more than 8 weeks. Second-line treatment comprises topical calcineurin inhibitors, phototherapy, and systemic treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Change history

  • 19 December 2017

    Unfortunately, the original publication of this article contained mistakes. The publisher introduced an error after proofreading where all occurrences of “topical corticosteroids” were typographically written as “topical corticost-effectivenesseroid”.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Meding B, Jä B. Incidence of hand eczema—a population-based retrospective study. J Invest Dermatol. 2004;122(4):873–7. Description of variations of incidence of hand eczema.

  2. Christoffers WA, Politiek K, Coenraads PJ, Van Der Schaft J, De Bruin-Weller MS, Schuttelaar MLA. Drug survival of cyclosporine in the treatment of hand eczema: a multicentre, daily use study. J Eur Acad Dermatology Venereol. 2016;30(1):63–6.

    Article  CAS  Google Scholar 

  3. Kumari V, Timm K, Kuhl AA, Heine G, Worm M. Impact of systemic alitretinoin treatment on skin barrier gene and protein expression in patients with chronic hand eczema. Br J Dermatol [Internet]. Dec;175(6):1243-1250. https://doi.org/10.1111/bjd.14921.

  4. Thaci D, Augustin M, Westermayer B, Kamps A, Hennig M. Effectiveness of alitretinoin in severe chronic hand eczema: PASSION, a real-world observational study. J Dermatolog Treat England. 2016;27(6):577–83.

    Article  Google Scholar 

  5. Diepgen TL, Andersen KE, Chosidow O, Coenraads PJ, Elsner P, English J, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges [Internet]. 2015;13(1):e1–22. Evidence and consensus-based guidelines on management of hand eczema.

  6. Antonov D, Schliemann S, Elsner P. Hand dermatitis: a review of clinical features, prevention and treatment. Am J Clin Dermatol. Springer Int Publishing. 2015;16(4):257–70.

    Article  Google Scholar 

  7. Hauber AB, Mohamed AF, Gonzalez JM, Otteson Fairchild A, Zelt SC, Graff O. Benefit-risk tradeoff preferences for chronic hand eczema treatments. J Dermatolog Treat. England. 2017;28(1):40–6.

    Article  CAS  Google Scholar 

  8. Sorensen JA, Fisker MH, Agner T, Clemmensen KKB, Ebbehoj NE. Associations between lifestyle factors and hand eczema severity: are tobacco smoking, obesity and stress significantly linked to eczema severity? Contact Dermatitis. England. 2017;76(3):138–45.

    Article  Google Scholar 

  9. Cvetkovski RS, Jensen H, Olsen J, Johansen JD, Agner T. Relation between patients’ and physicians’ severity assessment of occupational hand eczema 2005;153(3):596–600.

  10. Sørensen JA, Fisker MH, Agner T, Clemmensen KKB, Ebbehøj NE. Associations between lifestyle factors and hand eczema severity: are tobacco smoking, obesity and stress significantly linked to eczema severity? Contact Dermatitis [Internet]. 2017 Mar [cited 2017 Jun 16];76(3):138–45. Smoking cessation and other life style changes have been shown to be used in treatment of hand eczema.

  11. Brans R, Skudlik C, Weisshaar E, Gediga K, Scheidt R, Wulfhorst B, et al. Association between tobacco smoking and prognosis of occupational hand eczema: a prospective cohort study. Br J Dermatol. 2014;171(5):1108–15. Smoking cessation and other life style changes have been shown to be used in treatment of hand eczema.

  12. Anveden Berglind I, Alderling M, Meding B. Life-style factors and hand eczema. Br J Dermatol. 2011;165(3):568–75.

    Article  CAS  PubMed  Google Scholar 

  13. Hald M, Agner T, Blands J, Veien NK, Laurberg G, Avnstorp C, et al. Clinical severity and prognosis of hand eczema. Br J Dermatol. 2009;160(6):1229–36. Overview of factors influencing severity and prognosis of hand eczema.

  14. Blair HA, Scott LJ. Alitretinoin: a review in severe chronic hand eczema. Drugs New Zealand. 2016;76(13):1271–9. Clear overview of Alitretinoin as a treatment modality for hand eczema.

  15. Halling-Overgaard A-S, Zachariae C, Thyssen JP. Management of atopic hand dermatitis. Dermatol Clin United States. 2017;35(3):365–72.

    Article  CAS  Google Scholar 

  16. Held E, Skoet R, Johansen JD, Agner T. The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter- and intraobserver reliability. Br J Dermatol. 2005;152(2):302–7.

    Article  CAS  PubMed  Google Scholar 

  17. Coenraads PJ, Van Der Walle H, Ruzicka T, Dreno B, La Loge CD, Viala M, et al. Contact dermatitis and allergy. Construction and validation of a photographic guide for assessing severity of chronic hand dermatitis 2005;152(2):296–301.

  18. van der Meer EWC, Boot CRL, Jungbauer FHW, van der Klink JJL, Rustemeyer T, Coenraads PJ, et al. Hands4U: a multifaceted strategy to implement guideline-based recommendations to prevent hand eczema in health care workers: design of a randomised controlled trial and (cost) effectiveness evaluation. BMC Public Health [Internet]. 2011 Aug 25 [cited 2017 Jun 16];11(1):669. https://doi.org/10.1186/1471-2458-11-669.

  19. Coenraads P-J. Hand eczema is common and multifactorial. J invest Dermatol [internet]. Elsevier Masson SAS. 2007;127(7):1568–70.

    Article  CAS  Google Scholar 

  20. Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol[Internet]. 2011;164(2):415–28. The application of topical steroid twice weekly may be superior to treat flare ups in atopic dermatitis than the application of topical calcineurininhibitors, this knowledge may adapt to the treatment of acute flares in hand eczema.

  21. Hald M, Agner T, Blands J, Johansen JD. Delay in medical attention to hand eczema: a follow-up study. Br J Dermatol. 2009;161(6):1294–300.

    Article  CAS  PubMed  Google Scholar 

  22. Halling-Overgaard A-S, Zachariae C, Thyssen JP. Management of atopic hand dermatitis. Dermatol Clin [internet]. Elsevier Inc. 2017;35(3):365–72.

    Article  CAS  Google Scholar 

  23. Blair HA, Scott LJ. Alitretinoin: a review in severe chronic hand eczema. Drugs Springer International Publishing. 2016;76(13):1271–9.

    Google Scholar 

  24. Gritiyarangsan P, Sukhum A, Tresukosol P, Kullavanijaya P. Topical PUVA therapy for chronic hand eczema. J Dermatol. 1998;25(5):299–301.

    Article  CAS  PubMed  Google Scholar 

  25. Ibler KS, Jemec GB, Diepgen TL, Gluud C, Lindschou HJ, Winkel P, et al. Skin care education and individual counselling versus treatment as usual in healthcare workers with hand eczema: randomised clinical trial. Bmj. 2012;345(1756–1833 (Electronic))):e7822. First randomized trial on patient education on hand eczema in health care workers. Shows a statistically significant effect on both severity and quality of life in the intervention group compared to the control group.

  26. Carøe TK, Ebbehøj N, Agner T. A survey of exposures related to recognized occupational contact dermatitis in Denmark in 2010. Contact Dermatitis. 2013;70(1):56–62.

    Article  PubMed  Google Scholar 

  27. Van Gils RF, Boot CRL, Knol DL, Rustemeyer T, Van Mechelen W, Van Der Valk PGM, et al. The effectiveness of integrated care for patients with hand eczema: results of a randomized, controlled trial. Contact Dermatitis. 2012;66(4):197–204. Randomized controlled study on patient education in dermatological patients showing a statistically significant effect on the severity of hand eczema in the intervention group compared to the control group.

  28. Mollerup A, Veien NK, Johansen JD. Effectiveness of the healthy skin clinic—a randomized clinical trial of nurse-led patient counselling in hand eczema. Contact Dermatitis. 2014;71(4):202–14. Randmoized controlled study on patient education showing effect in favor of the intervention group.

  29. Zhai H, Maibach HI. Moisturizers in preventing irritant contact dermatitis: an overview. Contact dermatitis. 1998;38(5):241–4.

  30. Buraczewska I, Berne B, Lindberg M, Torma H, Loden M. Changes in skin barrier function following long-term treatment with moisturizers, a randomized controlled trial. Br J Dermatol [Internet]. 2007;156(3):492–8.

    Article  CAS  Google Scholar 

  31. Lodén M, Wirén K, Smerud KT, Meland N, Hønnas H, Mørk G, et al. The effect of a corticosteroid cream and a barrier-strengthening moisturizer in hand eczema. A double-blind, randomized, prospective, parallel group clinical trial. J Eur Acad Dermatology Venereol. 2012;26(5):597–601.

    Article  Google Scholar 

  32. Agner T. Hand eczema and tobacco: lifting the smoke screen. Br J Dermatol. 2014;171(5):933–4.

    Article  CAS  PubMed  Google Scholar 

  33. Molin S, Ruzicka T, Herzinger T. Smoking is associated with combined allergic and irritant hand eczema, contact allergies and hyperhidrosis. J Eur Acad Dermatology Venereol. 2015;29(12):2483–6.

    Article  CAS  Google Scholar 

  34. Meding B, Alderling M, Wrangsjö K. Tobacco smoking and hand eczema: a population-based study. Br J Dermatol. 2010;163(4):752–6.

    Article  CAS  PubMed  Google Scholar 

  35. Crane MM, Webb DJ, Watson E, Cunliffe T, English J. Hand eczema and steroid-refractory chronic hand eczema in general practice: prevalence and initial treatment. Br J Dermatol. England. 2017;176(4):955–64.

    Article  CAS  Google Scholar 

  36. Thelmo MC, Lang W, Brooke E, Osborne BE, McCarty MA, Jorizzo JL, et al. An open-label pilot study to evaluate the safety and efficacy of topically applied tacrolimus ointment for the treatment of hand and/or foot eczema. J Dermatolog Treat. 2003;14(3):136–40.

    Article  CAS  PubMed  Google Scholar 

  37. Luger T, Paul C. Potential new indications of topical calcineurin inhibitors. Dermatology. 2007;215(SUPPL. 1):45–54.

    Article  CAS  PubMed  Google Scholar 

  38. Kumari V, Timm K, Kuhl AA, Heine G, Worm M. Impact of systemic alitretinoin treatment on skin barrier gene and protein expression in patients with chronic hand eczema. Br J Dermatol England. 2016;175(6):1243–50.

    Article  CAS  Google Scholar 

  39. Politiek K, Christoffers WA, Coenraads PJ, Schuttelaar MLA. Alitretinoin and acitretin in severe chronic hand eczema; results from a retrospective daily practice study. Dermatol Ther. 2016;29(5):364–71.

    Article  PubMed  Google Scholar 

  40. Christoffers WA, Politiek K, Coenraads PJ, van der Schaft J, de Bruin-Weller MS, Schuttelaar MLA. Drug survival of cyclosporine in the treatment of hand eczema: a multicentre, daily use study. J Eur Acad Dermatol Venereol England. 2016;30(1):63–6.

    Article  CAS  Google Scholar 

  41. Egan CA, Rallis TM, Meadows KP, Krueger GG. Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx. J Am Acad Dermatol [Internet]. 1999;40(4):612–4.

    Article  CAS  Google Scholar 

  42. Politiek K, van der Schaft J, Christoffers WA, Coenraads PJ, van den Reek JMPA, de Jong EMGJ, et al. Drug survival of methotrexate treatment in hand eczema patients: results from a retrospective daily practice study. J Eur Acad Dermatol Venereol. England; 2016 Aug;30(8):1405-7 https://doi.org/10.1111/jdv.13253.

  43. Oosterhaven JAF, Politiek K, Schuttelaar M-LA. Azathioprine treatment and drug survival in patients with chronic hand eczema—results from daily practice. Contact Dermatitis England. 2017;76(5):304–7.

    Article  Google Scholar 

  44. Halpern SM, Anstey A V., Dawe RS, Diffey BL, Farr PM, Ferguson J, et al. Topical PUVA: guidelines for topical PUVA: a report of a workshop of the British Photodermatology Group. Br Assoc Dermatologists’ Manag Guidel. Br J Dermatol. 2000 Jan;142(1):22-31.

  45. Sezer E, Etikan I. Local narrowband UVB phototherapy vs. local PUVA in the treatment of chronic hand eczema. Photodermatol Photoimmunol Photomed. 2007;23(1):10–4.

    Article  PubMed  Google Scholar 

  46. Roelofzen JHJ, Aben KKH, van der Valk PGM, van Houtum JLM, van de Kerkhof PCM, Kiemeney LA. Coal tar in dermatology. J Dermatolog Treat [Internet]. 2007;18(6):329–34.

    Article  CAS  Google Scholar 

  47. Grönhagen C, Lidén C, Wahlgren CF, Ballardini N, Bergström A, Kull I, et al. Hand eczema and atopic dermatitis in adolescents: a prospective cohort study from the BAMSE project. Br J Dermatol. 2015;173(5):1175–82.

    Article  PubMed  Google Scholar 

  48. Mortz CG, Bindslev-Jensen C, Andersen KE. Hand eczema in The Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis (TOACS): prevalence, incidence and risk factors from adolescence to adulthood. Br J Dermatol [Internet]. 2014 Aug [cited 2017 Jun 16];171(2):313–23. https://doi.org/10.1111/bjd.12963.

  49. Agner T, Held E. Skin protection programmes. Contact Dermatitis. 2002;47(5):253–6.

    Article  PubMed  Google Scholar 

  50. Sell L, Flyvholm M-A, Lindhard G, Mygind K. Implementation of an occupational skin disease prevention programme in Danish cheese dairies. Contact Dermatitis [Internet]. 2005 Sep [cited 2017 Jun 16];53(3):155–61.

Download references

Author information

Authors and Affiliations

  1. Bispebjerg Hospital, Bispebjerg bakke 23, 2400, Copenhagen, Denmark

    Tamara Theresia Lund MD, PhD-student & Tove Agner MD, PhD

Authors
  1. Tamara Theresia Lund MD, PhD-student
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tove Agner MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tamara Theresia Lund MD, PhD-student.

Ethics declarations

Conflict of interest

Tamara Theresia Lund declares that she has no conflict of interest. Tove Agner reports other from Sanofi, outside the submitted work

Human and animal rights and informed consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

The original version of this article was revised: The publisher introduced an error after proofreading where all occurrences of “topical corticosteroids” were typographically written as “topical corticost-effectivenesseroid”.

This article is part of the Topical Collection on Contact Dermatitis

A correction to this article is available online at https://doi.org/10.1007/s40521-017-0150-4.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lund, T.T., Agner, T. Hand Eczema: Treatment Options. Curr Treat Options Allergy 4, 401–410 (2017). https://doi.org/10.1007/s40521-017-0148-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40521-017-0148-y

Keywords

Search

Navigation